Use of Intravenous Vitamin C in Severe COVID led to reduction in ICU stay and severity of Disease
Keywords:
COVID-19, Vitamin C, PlaceboAbstract
Background: A global health catastrophe has taken place as a result of the fast spread of COVID-19 throughout the globe. The most prevalent therapy to date has been symptomatic supportive therapy. In clinical studies on patients with bacterial-induced sepsis and acute respiratory distress syndrome (ARDS), a high dosage of intravenous VC (HIVC) was shown to inhibit numerous essential elements of cytokine storm. Objective: To determine the reduction in Intensive Care Unit (ICU) stay and severity of disease by using intravenous vitamin C and placebo in patients of COVID. Methodology: This randomized control trial study was conducted at two different COVID-19 ICU facilities at Ghurki Trust teaching hospital & Mid city COVID center. All the data of patient like name, sex, age and BMI were recorded in a specialized proforma. Patients in Group I received intravenous vitamin C and group II received placebo. Hospital stay was calculated as 14 days or less and >14 days. Results: A total of 120 patients were enrolled in which 76(63%) patients were males, 38 in each group and 44 (36.6%) patients were females, 22 in each group. In patients of group I, the mean was 58.69±16 years with mean BMI 27.24±4.8 kg/m2 and mean age in group II was 59.96±20 years with mean BMI 27.98±6.8 kg/m2. Number of patients in ≤14 days of hospital stay was greater (66.7%, n=40) in Group I, and in group II, 30 (50%) patients were observed. Conclusion: Our study concludes that the use of intravenous vitamin C in severe COVID affected patients help in reduction of ICU stay and severity of disease as compared to placebo.References
Delgado-Roche L, Mesta F. Oxidative stress as key player in severe acute respiratory syndrome coronavirus (SARS-CoV) infection. Arch Med Res. 2020;51(5):384-387.
Gavriilaki E, Anyfanti P, Gavriilaki M. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Curr Hypertens Rep. 2020;22(9):63.
Ragab D, Salah Eldin H, Taeimah M. The COVID-19 cytokine storm; what we know so far. Front Immunol. 2020;11:1446.
Woolum JA, Abner EL, Kelly A. Effect of thiamine administration on lactate clearance and mortality in patients with septic shock. Crit Care Med. 2018;46(11):1747-1752.
Annane D. Adrenal insufficiency in sepsis. Curr Pharm Des. 2008;14(19):1882-1886.
Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211.
MarikPE, KhangooraV, RiveraR. Hydrocortisone,vitamin C, and thiamine for the treatment of severe sepsis and septic shock. Chest. 2017;151(6):1229-1238.
Fujii T, Luethi N, Young PJ. Effect of vitamin C, hydro- cortisone, and thiamine versus hydrocortisone alone on time alive and free of vasopressor support among patients with septic shock: the vitamins randomized clinical trial. JAMA. 2020;323(5): 423-431.
Fowler AA III, Truwit JD, Hite RD. Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial. JAMA. 2019; 322(13):1261-1270.
Moskowitz A, Huang DT, Hou PC. Effect of ascorbic acid, corticosteroids, and thiamine on organ injury in septic shock: the ACTS randomized clinical trial. JAMA. 2020;324(7):642-650.
Cummings MJ, Baldwin MR, Abrams D. Epidemiology, clin- ical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020; 395(10239):1763-1770.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017;39:529-39.
Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCp). Med Rxiv. 2020.
Hemilä H, Chalker E. Vitamin C can shorten the length of stay in the ICU: a meta-analysis. Nutrients. 2019;11.
Fowler III AA, Kim C, Lepler L, Malhotra R, Debesa O, Natarajan R, et al. Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. World J Crit Care Med. 2017;6:85-90.
Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients. Ann Intensive Care. 201;11: 5.
Hoang BX, Shaw G, Fang W, Han B. Possible application of high-dose vitamin C in the prevention and therapy of coronavirus infection. J Glob Antimicrob Resist. 2020;23:256-62.
Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M. Vitamin C: Intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010;5.
Nathens AB, Neff MJ, Jurkovich GJ. Randomized, prospective trial of antioxidant supplementation in critically ill surgical patients. Ann Surg. 2002;236:814.
Hemilä H. Vitamin C and community-acquired pneumonia. Am J Respir Crit Care Med. 2011;184:621-22.
Fowler AA, Kim C, Lepler L, Malhotra R, Debesa O, Natarajan R. Intravenous vitamin C as adjunctive therapy for enterovirus/rhinovirus induced acute respiratory distress syndrome. World J Crit Care Med. 2017;6:85-90.
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China Intensive Care Med. 2020;46(5):846-8.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020;71(15):762-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Chest Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
